Data from the XTEND-Kids study presented at the 2023 International Society on Thrombosis and Haemostasis Congress showed that once-weekly prophylaxis with efanesoctocog alfa dosed at 50 IU/kg body weight was well tolerated and provided highly effective bleed protection and treatment in children <12 years of age with severe haemophilia A. These findings are consistent with the results of the XTEND-1 trial, which evaluated the efficacy of efanesoctocog alfa in both adults and adolescents.
No takes yet. Share an insight, caveat, or question.
Simoneau et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: